PGNYHealthcare · Healthcare PlansThe 12 Wall Street analysts covering Progyny, Inc. hold a median 12-month price target of $35 — +27.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Progyny, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (95): The business earns solid, repeatable profits on what it owns.
Revisions (49): Analysts have, on balance, been cutting their forecasts.
Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PGNY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +27.0% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | Wells Fargo | Initiates | Overweight | $37 |
| 8 Sept 2026 | Citizens | Maintains | Market Outperform | — |
| 8 Sept 2026 | Citizens | Maintains | Market Outperform | $31 → $33 |
| 21 Aug 2026 | JP Morgan | Maintains | Neutral | $27 → $30 |
| 21 Aug 2026 | JP Morgan | Maintains | Neutral | — |
| 20 Aug 2026 | Wells Fargo | Initiates | Overweight | $37 |
| 20 Aug 2026 | Wells Fargo | Initiates | Overweight | — |
| 13 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 13 Aug 2026 | Truist Securities | Maintains | Buy | $33 → $36 |
| 12 Aug 2026 | Barclays | Maintains | Equal-Weight | — |
| 12 Aug 2026 | Barclays | Maintains | Equal-Weight | $34 → $30 |
| 28 July 2026 | Barclays | Downgrade | Equal-Weight | $27 → $34 |
| 28 July 2026 | Barclays | Downgrade | Equal-Weight | — |
| 24 July 2026 | BTIG | Maintains | Buy | $30 → $40 |
| 24 July 2026 | BTIG | Maintains | Buy | — |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $30 → $36 |
| 13 July 2026 | Keybanc | Maintains | Overweight | — |
| 13 July 2026 | Keybanc | Maintains | Overweight | $30 → $35 |
| 22 June 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PGNY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Progyny, Inc. returned +37.7% against +17.7% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 28% of US stocks
Cheaper than 59% of US stocks
Cheaper than 23% of US stocks
Cheaper than 25% of US stocks
Higher than 40% of US stocks
Higher than 78% of US stocks
Higher than 28% of US stocks
Higher than 66% of US stocks
Higher than 62% of US stocks
Higher than 76% of US stocks
Higher than 92% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Progyny, Inc. has a market value of $2.0B and an enterprise value of $1.8B.
Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 5.3% year on year.
Net income over the same four quarters: $78.6M, a 6.0% net margin.
Diluted earnings per share, trailing twelve months: $0.92.
Free cash flow in the twelve months to 30 June 2026: $178.4M.
Progyny, Inc. spent $230.3M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 28.2×; forward P/E: 11.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Progyny, Inc. employs 835 people — $1.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| PGNYProgyny, Inc. | $2.0B | 96 |
| CLOVClover Health Investments Corp. | $2.4B | 70 |
| ALHCAlignment Healthcare, Inc. | $1.7B | 65 |
| OSCROscar Health, Inc. | $9.6B | 89 |
| MOHMolina Healthcare, Inc. | $10.0B | 36 |
| CNCCentene Corp. | $31.8B | 96 |
| VCELVericel Corp.* | $2.0B | 94 |
* Nearest Healthcare names by size — few healthcare plans companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Progyny, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research compares Progyny and Charles River Laboratories as Medical Services stocks, asking which may be the better value for investors seeking undervalued stocks.
Why it matters — The item frames PGNY in a valuation comparison with CRL but provides no conclusion in the excerpt.
Progyny said its current selling season is pacing toward a record level, with commitments received to date and anticipated remaining decisions expected to contribute 1.2 million new covered lives from launches in the first half of 2027. The company said employers are increasingly evaluating solutions for savings, total cost management and return on investment amid rising medical costs.
Why it matters — The update offers a view of employer demand and potential covered-life additions relevant to Progyny’s business.
Zacks Investment Research compares Progyny (PGNY) and Charles River Laboratories (CRL) as potential value options within the Medical Services sector. The piece poses the question of which of these two stocks offers investors the better value opportunity at this time.
Why it matters — The article provides a value-focused comparison that PGNY watchers could use to gauge how the company is positioned relative to a peer in the same sector.
Seeking Alpha highlights Progyny as the US market leader in fertility benefits management, citing robust growth, improving margins, and Q2 2026 results showing 11% revenue growth ex-Amazon with near-100% EPS growth guidance for 2026. The article notes secular tailwinds that position the company for sustained double-digit growth.
Why it matters — PGNY watchers would note the article's emphasis on margin expansion, EPS growth guidance, and sustained market leadership amid growing fertility-benefits demand.
Wall Street analysts' mean price target for Progyny (PGNY) points to a roughly 25.2% upside in the stock, according to Zacks Investment Research. The report notes that while price-target metrics have not proven highly effective, strong agreement among analysts in raising earnings estimates suggests upside potential.
Why it matters — PGNY watchers would care because the report highlights analyst confidence in the stock, reflected in both price targets and upward earnings estimate revisions.
The 12 Wall Street analysts covering Progyny, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Progyny, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Progyny, Inc. 96 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Progyny, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (95 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +27.0% from the last close, and Ticker Nerd's factor model ranks Progyny, Inc. 96 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Progyny, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PGNY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.
Progyny, Inc. returned +37.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Progyny Inc is a healthcare benefits management company that provides fertility, family-building, and women’s health solutions for employers. Progyny designs integrated benefit programs that combine clinical expertise, personalized member support, selective provider networks, and pharmacy benefits to help organizations offer specialized reproductive and lifecycle care.
The most recent item we track (Zacks Investment Research, 7 Oct 2026): "PGNY or CRL: Which Is the Better Value Stock Right Now?". Zacks Investment Research compares Progyny and Charles River Laboratories as Medical Services stocks, asking which may be the better value for investors seeking undervalued stocks.
Progyny Inc is a healthcare benefits management company that provides fertility, family-building, and women’s health solutions for employers. Progyny designs integrated benefit programs that combine clinical expertise, personalized member support, selective provider networks, and pharmacy benefits to help organizations offer specialized reproductive and lifecycle care. Its services support areas such as fertility treatment, pregnancy and postpartum care, menopause and midlife support, and benefit navigation for adoption and surrogacy reimbursement. Progyny serves employers across multiple industries that want to include comprehensive family-building and women’s health coverage in their employee benefits packages. The company operates as a focused specialist in employer-sponsored healthcare benefits, playing a distinct role in making complex care pathways easier to manage for members, providers, and benefits administrators.
CEO Mr. Peter Anevski CPA · 835 employees · United States · https://www.progyny.com
